Wird geladen...
Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer
Cisplatin resistance remains a major problem in the treatment of lung cancer. We have discovered that cisplatin resistant (CR) lung cancer cells, regardless of the signaling pathway status, share the common parameter which is an increase in reactive oxygen species (ROS) and undergo metabolic reprogr...
Gespeichert in:
| Veröffentlicht in: | Oncotarget |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Impact Journals LLC
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5564767/ https://ncbi.nlm.nih.gov/pubmed/28525376 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17568 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|